1 – 20 of 39
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : An observational cohort study
2023) In Journal of Neurology, Neurosurgery and Psychiatry(
- Contribution to journal › Article
- 2019
-
Mark
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
(
- Contribution to journal › Article
-
Mark
High Graft-versus-Host Disease-Free, Relapse/Rejection-Free Survival and Similar Outcome of Related and Unrelated Allogeneic Stem Cell Transplantation for Aplastic Anemia : A Nationwide Swedish Cohort Study
(
- Contribution to journal › Article
- 2018
-
Mark
Low response rate to ATG-based immunosuppressive therapy in very severe aplastic anaemia - A Swedish nationwide cohort study
(
- Contribution to journal › Article
- 2017
-
Mark
Incidence and outcome of acquired aplastic anemia : Real-world data from patients diagnosed in Sweden from 2000–2011
(
- Contribution to journal › Article
-
Mark
Long-term survival of patients with CLL after allogeneic transplantation : A report from the European Society for Blood and Marrow Transplantation
(
- Contribution to journal › Article
- 2016
-
Mark
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
(
- Contribution to journal › Article
- 2015
-
Mark
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.
(
- Contribution to journal › Article
-
Mark
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
(
- Contribution to journal › Article
-
Mark
Being a haematopoietic stem cell donor for a sick sibling: Adult donors' experiences prior to donation.
(
- Contribution to journal › Article
-
Mark
Outcome and risk factor analysis of molecular subgroups in cytogenetically normal AML treated by allogeneic transplantation.
(
- Contribution to journal › Article
-
Mark
Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
(
- Contribution to journal › Article
-
Mark
Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation.
(
- Contribution to journal › Article
- 2014
-
Mark
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
(
- Contribution to journal › Article
-
Mark
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
(
- Contribution to journal › Article
-
Mark
Having a sibling as donor: Patients' experiences immediately before allogeneic hematopoietic stem cell transplantation.
(
- Contribution to journal › Article
- 2013
-
Mark
Potential adult sibling stem cell donors' perceptions and opinions regarding an information and care model.
(
- Contribution to journal › Article
-
Mark
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
(
- Contribution to journal › Article
- 2012
-
Mark
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
(
- Contribution to journal › Article
-
Mark
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
(
- Contribution to journal › Article